Serum tumour associated trypsin inhibitor, as a biomarker for survival in renal cell carcinoma

References

• Wahlgren T, Harmenberg U, Sandstrom P, et al. Treatment and overall survival in renal cell carcinoma: a Swedish population-based study (2000–2008). Br J Cancer. 2013;108(7):1541–1549.
   PubMed Web of Science ®Google Scholar
• Janzen NK, Kim HL, Figlin RA, et al. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003;30(4):843–852.
   PubMed Web of Science ®Google Scholar
• Leibovich BC, Blute ML, Cheville JC, et al. Prediction of progression after radical nephrectomy for patients with clear cell renal cell carcinoma: a stratification tool for prospective clinical trials. Cancer. 2003;97(7):1663–1671.
   PubMed Web of Science ®Google Scholar
• Heng DY, Xie W, Regan MM, et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Cin Oncol. 2009;27(34):5794–5799.
   PubMed Web of Science ®Google Scholar
• Ljungberg B, Albiges L, Abu-Ghanem Y, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799–810.
   PubMed Web of Science ®Google Scholar
• Huhtala ML, Pesonen K, Kalkkinen N, et al. Purification and characterization of a tumor-associated trypsin inhibitor from the urine of a patient with ovarian cancer. J Biol Chem. 1982;257(22):13713–13716.
   PubMed Web of Science ®Google Scholar
• Itkonen O, Stenman UH. TATI as a biomarker. Clin Chim Acta. 2014;431:260–269.
   PubMed Web of Science ®Google Scholar
• Paju A, Jacobsen J, Rasmuson T, et al. Tumor associated trypsin inhibitor as a prognostic factor in renal cell carcinoma. J Urol. 2001;165(3):959–962.
   PubMed Web of Science ®Google Scholar
• Lukkonen A, Lintula S, von Boguslawski K, et al. Tumor-associated trypsin inhibitor in normal and malignant renal tissue and in serum of renal-cell carcinoma patients. Int J Cancer. 1999;83(4):486–490.
   PubMed Web of Science ®Google Scholar
• Tramonti G, Ferdeghini M, Donadio C, et al. Serum levels of tumor associated trypsin inhibitor (TATI) and glomerular filtration rate. Ren Fail. 1998;20(2):295–302.
   PubMed Web of Science ®Google Scholar
• Tramonti G, Ferdeghini M, Donadio C, et al. Tumor-associated trypsin inhibitor (TATI) and renal function. Kidney Int Suppl. 1997;63:S179–S81.
   PubMedGoogle Scholar
• Ogawa M, editor Serum Pancreatic Secretory Trypsin Inhibitor as a Sensitive Marker of Tissue Damage. The Strangeways Research Laboratory 75th Anniversary Symposium; 1987 the 6–8th of April 1987; Cambridge: Arthritis & Rheumatism.
   Google Scholar
• Ogawa M. Pancreatic secretory trypsin inhibitor as an acute phase reactant. Clin Biochem. 1988;21(1):19–25.
   PubMed Web of Science ®Google Scholar
• Paju A, Vartiainen J, Haglund C, et al. Expression of trypsinogen-1, trypsinogen-2, and tumor-associated trypsin inhibitor in ovarian cancer: prognostic study on tissue and serum. Clin Cancer Res. 2004;10(14):4761–4768.
   PubMed Web of Science ®Google Scholar
• Peltonen R, Osterlund P, Lempinen M, et al. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases. Tumour Biol. 2018;40(1):1010428317752944.
   Google Scholar
• Kozakiewicz B, Chądzyńska M, Dmoch-Gajzlerska E, et al. Monitoring the treatment outcome in endometrial cancer patients by CEA and TATI. Tumour Biol. 2016;37(7):9367–9374.
   PubMedGoogle Scholar
• Ravaud A, Motzer RJ, Pandha HS, et al. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy. N Engl J Med. 2016;375(23):2246–2254.
   PubMed Web of Science ®Google Scholar
• Eble JL, Sauter G, Epstein JI, et al. Pathology and genetics of the tumours of the genitourinary system and male genital organs. WHO classification of tumours. 2004 ed. Lyon: IARC; 2004.
   Google Scholar
• Sobim LG, Wittekind C. UICC International Union against cancer. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009.
   Google Scholar
• Ficarra V, Martignoni G, Maffei N, et al. Original and reviewed nuclear grading according to the Fuhrman system: a multivariate analysis of 388 patients with conventional renal cell carcinoma. Cancer. 2005;103(1):68–75.
   PubMed Web of Science ®Google Scholar
• Osman S, Turpeinen U, Itkonen O, et al. Optimization of a time-resolved immunofluorometric assay for tumor-associated trypsin inhibitor (TATI) using the streptavidin-biotin system. J Immunol Methods. 1993;161(1):97–106.
   PubMed Web of Science ®Google Scholar
• McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies (REMARK). J Natl Cancer Inst. 2005;97(16):1180–1184.
   PubMed Web of Science ®Google Scholar
• Lasson A, Borgstrom A, Ohlsson K. Elevated Pancreatic Secretory trypsin inhibitor levels during severe inflammatory disease, renal insufficiency, and after various surgical procedures. Scand J Gastroenterol. 1986;21(10):1275–1280.
   PubMed Web of Science ®Google Scholar
• Kim SP, Thompson RH, Boorjian SA, et al. Comparative effectiveness for survival and renal function of partial and radical nephrectomy for localized renal tumors: a systematic review and meta-analysis. J Urol. 2012;188(1):51–57.
   PubMed Web of Science ®Google Scholar
• Mariusdottir E, Jonsson E, Marteinsson VT, et al. Kidney function following partial or radical nephrectomy for renal cell carcinoma: a population-based study. Scand J Urol. 2013;47(6):476–482.
   PubMed Web of Science ®Google Scholar
• Winer AG, Zabor EC, Vacchio MJ, et al. The effect of patient and surgical characteristics on renal function after partial nephrectomy. Clin Genitourin Cancer. 2018;16(3):191–196.
   PubMed Web of Science ®Google Scholar
• Tsuzuki T, Iwata H, Murase Y, et al. Renal tumors in end-stage renal disease: a comprehensive review. Int J Urol. 2018;25(9):780–786.
   PubMed Web of Science ®Google Scholar
• Tusong H, Maolakuerban N, Guan J, et al. Functional analysis of serum microRNAs miR-21 and miR-106a in renal cell carcinoma. Cancer Biomark. 2017;18(1):79–85.
   PubMed Web of Science ®Google Scholar
• Nuerrula Y, Rexiati M, Liu Q, et al. Differential expression and clinical significance of serum protein among patients with clear-cell renal cell carcinoma. CBM. 2015;15(4):485–491.
   Google Scholar
• Rasanen K, Itkonen O, Koistinen H, et al. Emerging roles of SPINK1 in cancer. Clin Chem. 2016;62(3):449–457.
   PubMed Web of Science ®Google Scholar
• Semeniuk-Wojtaś A, Lubas A, Stec R, et al. Neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, and C-reactive protein as new and simple prognostic factors in patients with metastatic renal cell cancer treated with tyrosine kinase inhibitors: a systemic review and meta-analysis. Clin Genitourin Cancer. 2018;16(3):e685–e693.
   PubMed Web of Science ®Google Scholar